window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : February 1, 2026

  • News
  • About Us
Contact Us

biotech funding

  • Artificial Intelligence,Drug Development,European biotech,Partnerships & Funding,Technology and platforms

    FluoSphera raises €1.23 million to scale human-based preclinical testing platform

    Swiss biotech startup FluoSphera has raised €1.23 million (CHF 1.15 [...]

    January 12, 2026
  • Cell & Gene Therapy,Clinical Development,Clinical Trials,European biotech,Partnerships & Funding,Patient Centricity

    Anocca raises SEK 440M to advance TCR-T cell therapies into clinical development

    Swedish clinical-stage biotech Anocca AB has secured approximately SEK 440 [...]

    August 19, 2025
  • CDMOs & Manufacturing,Market Access & Commercialization,Partnerships & Funding,Research & Development

    Growing investor interest shifts toward mature UK life science companies amid regional funding imbalances

    New research from Pioneer Group, in collaboration with Beauhurst, reveals [...]

    August 7, 2025
  • Biologics & Biosimilars,Drug Development,Global health,Partnerships & Funding,Regulatory Affairs,Research & Development

    Centauri Therapeutics secures $5.1M from CARB-X to advance ABX-01 to first-in-human trials

    Centauri aims to start first-in-human clinical study for broad-spectrum immunotherapy [...]

    July 29, 2025
  • Clinical Trials,European biotech,Partnerships & Funding,Women's Health

    Non-hormonal endometriosis drug backed by new investors in Gesynta Pharma round

    Gesynta Pharma has announced the second closing of its Series [...]

    July 23, 2025
  • Clinical Development,Market Access & Commercialization,Oncology,Partnerships & Funding

    VIVES Partners joins Nuclidium AG’s €84M Series B Financing to advance copper-based radiopharmaceuticals

    VIVES Partners, managing company of VIVES Funds, has joined a [...]

    July 10, 2025
  • Clinical Trials,Oncology,Partnerships & Funding

    Enterome secures $19M to progress OncoMimics immunotherapy in indolent non-Hodgkin lymphoma

    Funding to advance EO2463 through Phase 1/2 and prepare for [...]

    June 12, 2025
  • Biologics & Biosimilars,CDMOs & Manufacturing,Cell & Gene Therapy,Regulatory Affairs

    Is Europe rising? How global pharma uncertainty is fuelling a new era for European innovation

    As global pharma grapples with shifting regulations, rising geopolitical tensions, [...]

    June 8, 2025
  • Artificial Intelligence,Drug Development,Partnerships & Funding,Precision medicine,Technology and platforms

    Biostate AI raises $12M to build the ‘Netflix’ of molecular diagnostics using RNAseq and GenAI

    Biostate AI has raised $12 million in Series A funding [...]

    May 23, 2025
  • Artificial Intelligence,Clinical Trials

    PhaseV raises $50M to expand AI-powered clinical trial platform

    PhaseV has secured $50 million in Series A funding to [...]

    May 13, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Evestia Clinical acquires ICRC-Weyer to expand full-service clinical research in Europe
    Categories: Biotech, CDMOs & Manufacturing, Clinical Development, Clinical Trials, Partnerships & Funding
  • Mental health systems strain as demand and funding shifts drive push for multimodal care
    Categories: Digital Health, Healthcare leadership, Medical devices, Mental health, Regulatory Affairs
  • Nine-gene signature linked to lapatinib resistance in HER2-positive breast cancer
    Categories: Clinical studies, Drug Development, Oncology, Precision medicine, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top